Contortrostatin
Alternative Names: PB 2Latest Information Update: 24 Oct 2021
At a glance
- Originator University of Southern California
- Developer Pivotal BioSciences; University of Southern California
- Class Antiplatelets; Cytostatics; Disintegrins
- Mechanism of Action Integrin inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours; Thrombosis
Most Recent Events
- 14 Dec 2007 Preclinical development for Solid tumours is ongoing
- 14 Dec 2007 Discontinued - Preclinical for Thrombosis in USA (IV)
- 14 Jun 2004 Contortrostatin licensed to Pivotal BioSciences worldwide